Factors associated with successful discontinuation of hormone therapy

Journal of Women's Health

Volumn 23, Issue 5, 2014, Pages 382-388

  Newton, Katherine M ^a,b   Reed, Susan D ^a,b,c,d   Nekhyludov, Larissa ^e,f   Grothaus, Louis C ^a   Ludman, Evette J ^a   Ehrlich, Kelly ^a   LaCroix, Andrea Z ^a,b,d  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; COPING BEHAVIOR; DEPRESSION; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYSTERECTOMY; MOOD CHANGE; MOOD DISORDER; PILL; PRIORITY JOURNAL; SLEEP DISORDER; TELEPHONE INTERVIEW; TREATMENT WITHDRAWAL; VAGINA BLEEDING;

AGED; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HEALTH SURVEYS; HOT FLASHES; HUMANS; INTERVIEWS AS TOPIC; MASSACHUSETTS; MEDICATION ADHERENCE; MENOPAUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGESTINS; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 84899962037     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2012.4200     Document Type: Article

References (30)

1. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-1050.
2. MacLennan AH, Gill TK, Broadbent JL, Taylor AW. Continuing decline in hormone therapy use: Population trends over 17 years. Climacteric 2009;12:122-130.
3. Board of Trustees NAMS. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 2007;14:168-182.
4. Buist DS, Anderson ML, Reed SD, et al. Short-term hormone therapy suspension and mammography recall: A randomized trial. Ann Intern Med 2009;150:752-765.
5. Reed SD, Buist DS, Anderson ML, et al. Short-term (1-2 mo) hormone therapy cessation before mammography. Menopause 2009;16:1125-1131.
6. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102:1233-1239.
7. Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord 2009;114:163-173.
8. Wiklund I, Holst J, Karlberg J, et al. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992;14:211-224.
9. Newton K, LaCroix A, Leveille S, Rutter C, Keenan N, Anderson L. Women's beliefs and decisions about hormone replacement therapy. J Womens Health 1997;6:459-465.
10. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
11. Hunter M, O'Dea I, Britten N. Decision-making and hormone replacement therapy: A qualitative analysis. Soc Sci Med 1997;45:1541-1548.
12. Kaufert P, Boggs P, Ettinger B, Woods N, Utian W. Women and menopause: Beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey. Menopause 1998;5:197-202.
13. Marmoreo J, Brown JB, Batty HR, Cummings S, Powell M. Hormone replacement therapy: Determinants of women's decisions. Patient Educ Couns 1998;33:289-298.
14. Newton K, LaCroix A, Leveille S, Rutter C, Keenan N, Anderson L. The physician's role in women's decision making about hormone replacement therapy. Obstet Gynecol 1998;92:580-584.
15. Bush TM, Bonomi AE, Nekhlyudov L, et al. How the Women's Health Initiative (WHI) influenced physicians' practice and attitudes. J Gen InternMed 2007;22:1311-1316.
16. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045.
17. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA 2011;305:1305-1314.
18. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70.
19. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: The Harvard study of moods and cycles. Arch Gen Psychiatry 2006;63:385-390.
20. Ness J, Aronow WS, Newkirk E, McDanel D. Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial. J Gerontol A Biol Sci Med Sci 2005;60:460-462.
21. Rolnick SJ, Kopher RA, DeFor TA, Kelley ME. Hormone use and patient concerns after the findings of the Women's Health Initiative. Menopause 2005;12:399-404.
22. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193.
23. Barber CA, Margolis K, Luepker RV, Arnett DK. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: The Minnesota Heart Survey (2000-2002). J Womens Health (Larchmt) 2004;13: 975-985.
24. Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 2006; 53:356-361.
25. Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: An observational study of tapering versus quitting cold turkey: Is there a difference in recurrence of menopausal symptoms? Menopause 2009; 16:494-499.
26. Lindh-Astrand L, Bixo M, Hirschberg AL, Sundstrom-Poromaa I, Hammar M. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause 2010; 17:72-79.
27. Cunha EP, Azevedo LH, Pompei LM, et al. Effect of abrupt discontinuation versus gradual dose reduction of postmenopausal hormone therapy on hot flushes. Climacteric 2010; 13:362-367.
28. Speroff L. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Climacteric 2010;13:429-432.
29. Casanova G, Radavelli S, Lhullier F, Spritzer PM. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause. Fertil Steril 2009;92:605-612.
30. Stevenson JC, Durand G, Kahler E, Pertynski T. Oral ultralow dose continuous combined hormone replacement therapy with 0.5 mg 17beta-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study. Maturitas 2010;67:227-232.